The National Cancer Institute (NCI) spends upwards of $4.9 billion each year on cancer research.

Stocks wavered around the unchanged mark in afternoon trade Monday, as investors paused following the biggest weekly gains for major indexes in more than a year.

There is a critical medical need for Bioniche's technology in a $1 billion market virtually free of real competition, which opens the door for massive revenue growth, while the sound financials limits downside risk. Overall, today's $0.20 share price appears to me as an excellent entry point...

TWTR was grounded on Monday, after falling a total of 19.02% over a two-day period. Meanwhile, the solar sector continued to recover from its early-December slump.